| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8805954 | European Annals of Otorhinolaryngology, Head and Neck Diseases | 2018 | 4 Pages |
Abstract
Dexamethasone is part of the management strategy for patients with Ménière's disease refractory to conventional treatment, implemented before destructive treatment. It achieves control of vertigo in 70% of patients at 2 years.
Related Topics
Health Sciences
Medicine and Dentistry
Otorhinolaryngology and Facial Plastic Surgery
Authors
A. Weckel, M. Marx, M.-J. Esteve-Fraysse,